Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at City of Hope

Sites in Duarte, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1038
Shown on this page
12
Current sort
Recently updated
Campus scope
City of Hope, Duarte, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within City of Hope, Duarte, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 145–156 of 1,038 matching trials with a site at City of Hope, Duarte, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

NCT05869682
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

NCT03354728
Status at this site: Recruiting
View directory record Official record
Conditions
Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Interventions
Laboratory Biomarker Analysis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677
Status at this site: Recruiting
View directory record Official record
Conditions
Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Interventions
Surgery, Preoperative chemotherapy
Procedure · Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

NCT04071236
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Duarte, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

NCT05384769
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Liquid Biopsy, Low Dose Computed Tomography of the Chest, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
50 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT04172532
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Duarte, California • Irvine, California • Orange, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

NCT06260033
Status at this site: Recruiting
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

NCT04548752
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
533
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Hurria Older PatiEnts (HOPE) With Breast Cancer Study

NCT01472094
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

NCT07061951
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Recruiting Phase 2 Interventional

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions
TAS6417, CYP Cocktail, Transporter Cocktail
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 5:20 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

NCT04783415
Site status not listed — check the official record
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Ublituximab, Umbralisib
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 5:20 PM EDT

About this City of Hope institution page

What this page lists
ClinicalTrials.gov records that list City of Hope in Duarte, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.